Houston Methodist is researching the effect of virtual reality on cancer patients. Photo courtesy of Houston Methodist

Virtual reality goes far beyond playing games with titles like Arizona Sunshine, Moss, Robo Recall, and Tetris Effect. VR also is playing an ever-growing role in health care settings. The global market for VR in health care could reach $3.8 billion in 2020, according to one estimate.

VR is touching all corners of heath, including robotic surgeries, training, pain management, and behavior modification, according to InterbrandHealth, a health care branding agency. And these technologies are happening right here in Houston.

Researchers at Houston Methodist Cancer Center are exploring whether exposure to nature, through either a real garden or VR, can ease pain and distress in cancer patients who are undergoing chemotherapy. This approach might decrease the need for prescription painkillers.

Houston Methodist and Texas A&M University are leading this test. Renee Stubbins, a clinical dietitian at Houston Methodist Cancer Center, and Ashley Verzwyvelt, an infusion oncology nurse at the cancer center, proposed the research after several years of studying ways that nature can boost the healing process.

"Anything that affects our patients' comfort — including easing pain and anxiety, and possibly reducing the need for pain medications — is important to their recovery," Stubbins says in a release. "People have an innate connection to nature, and we hope the patients will respond positively."

Three dozen cancer patients receiving chemotherapy infusions every two weeks during at least six cycles will be randomly assigned to one of three rooms: a live-garden-view room; a window-less room, and a room where nature can be experienced through a VR headset.

Teaming up with Houston-based Skyline Art Services, local artist Gonzo247 produced a nature-inspired mural on a wall behind the live garden to create an immersive environment. The mural depicts a flowering garden, blue sky and sunset that enhance the live garden of Texas wildflowers in the foreground.

Researchers will measure pain, distress, blood pressure, heart rate, and saliva cortisol at the beginning and end of each infusion visit. Saliva cortisol, a hormone produced when the body is stressed, helps gauge a patient's condition.

"If this study proves that real or virtual elements of nature help the healing process, then it has potential to positively impact our patients," Verzwyvelt says. "Some of them are hesitant to take pain medication due to concerns of addiction and adverse side effects, so I'm excited to see the possibilities this kind of research could bring."

Houston Methodist Cancer Center says the VR experiment could have implications for treatment of an array of patients who are immobile or whose immune systems are compromised.

"We looked at multiple studies that showed exposure to nature can reduce stress levels and actually increase productivity and creativity," says Ann McNamara, associate professor in the Department of Visualization at Texas A&M. "We want to see if we can reproduce those effects in a natural environment in virtual reality."

The study is being financed by the Center for Health & Nature, a joint initiative of Houston Methodist, Texas A&M and Texan by Nature, a nonprofit conservation group founded by former first lady Laura Bush. The Center for Health & Nature, housed at Houston Methodist Hospital, debuted in 2018.

"There's a gap in research regarding what nature factors lead to increased health, what exposure to nature means, and how much exposure is needed," Bush said when the center was announced.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.